SA MARKS HISTORIC HIV BREAKTHROUGH
South Africa has become the first country in Africa to approve Lenacapavir, a groundbreaking twice-yearly injection by Gilead Sciences that prevents HIV infection.
Approved by the South African Health Products Regulatory Authority (SAHPRA), Lenacapavir demonstrated near-complete efficacy in global clinical trials, offering new hope in a nation where millions live with HIV.
Supported by a R513-million Global Fund grant, rollout begins in April 2026, targeting vulnerable groups including pregnant and breastfeeding women, men who have sex with men, and sex workers.
With generic versions expected from 2027, Lenacapavir could reshape HIV prevention, bringing the goal of ending the epidemic closer than ever before.
Full story - https://t.co/wHqslVsfnl
Pictured - Boitumelo Semete-Makokotlela, SAHPRA CEO
🏆 CHAMPIONS OF THE WORLD! 🇿🇦
A 5 wicket victory! The Proteas Men have conquered the Test arena, winning the ICC World Test Championship 2025 Final against Australia at the iconic Lord’s Cricket Ground 🏟️🙌
Undeniable. Unstoppable. Unrelenting. History made at the Home of Cricket.
South Africa, this one’s for you! 🫵🇿🇦🏏
#WTCFinal #WozaNawe #ProteasWTCFinal
“If there is one thing that our history has taught us, it is that diplomacy and dialogue are more powerful than any weapon.”
~ President @CyrilRamaphosa
Ukraine Official Visit
One day, when it's safe, when there's no personal downside to calling a thing what it is, when it's too late to hold anyone accountable, everyone will have always been against this.
Situation in the State of Palestine:
#ICC Pre-Trial Chamber I rejects the State of Israel’s challenges to jurisdiction and issues warrants of arrest for Benjamin Netanyahu and Yoav Gallant. Learn more ⤵️ https://t.co/opHUjZG8BL
The day concluded with an update on the priorities of the new EU support project for the AGA and APSA.
Discussions covered the project's focus and implementation modalities.
@MakiTessema, @miapenning, and Demelash Alemu provided a detailed briefing on the current status.